Great Point Partners 13F annual report

Great Point Partners is an investment fund managing more than $522 billion ran by Dr. M.d.. There are currently 33 companies in M.d.’s portfolio. The largest investments include UroGen Pharma Ltd and Neurogene Inc, together worth $85.3 billion.

$522 billion Assets Under Management (AUM)

As of 7th August 2024, Great Point Partners’s top holding is 2,906,259 shares of UroGen Pharma Ltd currently worth over $48.8 billion and making up 9.3% of the portfolio value. Relative to the number of outstanding shares of UroGen Pharma Ltd, Great Point Partners owns less than approximately 0.1% of the company. In addition, the fund holds 1,004,291 shares of Neurogene Inc worth $36.5 billion. The third-largest holding is Abivax Sa worth $32.7 billion and the next is Merus N.V worth $31 billion, with 523,288 shares owned.

Currently, Great Point Partners's portfolio is worth at least $522 billion. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Great Point Partners

The Great Point Partners office and employees reside in Greenwich, Connecticut. According to the last 13-F report filed with the SEC, Dr. M.d. serves as the Senior Managing Member at Great Point Partners.

Recent trades

In the most recent 13F filing, Great Point Partners revealed that it had opened a new position in Neurogene Inc and bought 1,004,291 shares worth $36.5 billion.

The investment fund also strengthened its position in UroGen Pharma Ltd by buying 2,346,259 additional shares. This makes their stake in UroGen Pharma Ltd total 2,906,259 shares worth $48.8 billion. UroGen Pharma Ltd dropped 33.9% in the past year.

On the other hand, there are companies that Great Point Partners is getting rid of from its portfolio. Great Point Partners closed its position in Vaxcyte on 14th August 2024. It sold the previously owned 800,000 shares for $38.4 billion.

One of the average hedge funds

The two most similar investment funds to Great Point Partners are Walter Public Investments and Ratio Wealth. They manage $523 billion and $523 billion respectively.


Dr. M.d. investment strategy

Great Point Partners’s portfolio is diversified across 3 sectors. Currently, their heaviest sector is Health Care — making up 61.5% of the total portfolio value. The fund focuses on investments in the United States as 54.5% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are small-cap stocks. Stocks with a size of more than $100 million in market cap make up 9% of the total holdings value. On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $1.02 billion.

The complete list of Great Point Partners trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security Shares Owned Value Allocation
UroGen Pharma Ltd
418.97%
2,906,259
$48,767,026,000 9.34%
Vaxcyte, Inc.
Closed
800,000
$38,360,000,000
Neurogene Inc
Opened
1,004,291
$36,546,149,000 7.00%
Xenon Pharmaceuticals Inc
Closed
850,000
$33,515,500,000
Abivax Sa
Opened
2,472,188
$32,682,325,000 6.26%
Merus N.V
Opened
523,288
$30,962,951,000 5.93%
RAPT Therapeutics, Inc.
Closed
1,436,569
$28,444,066,000
Pliant Therapeutics, Inc.
99.33%
2,636,864
$28,346,288,000 5.43%
Arcellx Inc
Opened
492,000
$27,153,480,000 5.20%
Alpine Immune Sciences Inc
Closed
3,637,718
$26,737,227,000
Dynavax Technologies Corp.
Opened
2,374,000
$26,660,020,000 5.11%
Evolus Inc
1,188.18%
2,451,772
$26,601,726,000 5.10%
Cytokinetics Inc
Opened
474,202
$25,692,264,000 4.92%
Jazz Pharmaceuticals plc
Closed
160,000
$25,489,600,000
Seagen Inc
Closed
160,500
$20,625,855,000
Dianthus Therapeutics Inc
Opened
757,929
$19,615,203,000 3.76%
Point Biopharma Global Inc
Closed
2,541,779
$18,529,569,000
IVERIC bio Inc
Closed
825,000
$17,663,250,000
Insmed Inc
Opened
250,000
$16,750,000,000 3.21%
Zura Bio Ltd
Opened
4,642,241
$16,247,844,000 3.11%
Aclaris Therapeutics Inc
Closed
1,019,282
$16,053,692,000
Heron Therapeutics Inc
Closed
6,360,161
$15,900,403,000
Ultragenyx Pharmaceutical In
Closed
342,300
$15,858,759,000
KalVista Pharmaceuticals Inc
26.78%
1,338,568
$15,768,331,000 3.02%
Ionis Pharmaceuticals Inc
Opened
330,000
$15,727,800,000 3.01%
Context Therapeutics Inc
Opened
7,419,355
$14,875,807,000 2.85%
Amicus Therapeutics Inc
Opened
1,495,500
$14,835,360,000 2.84%
OptiNose Inc
73.88%
13,727,097
$14,276,181,000 2.73%
Ventyx Biosciences Inc
Closed
400,695
$13,138,789,000
Esperion Therapeutics Inc Ne
Opened
5,791,594
$12,857,339,000 2.46%
Voyager Therapeutics Inc
Opened
1,601,527
$12,668,079,000 2.43%
Outlook Therapeutics Inc
Opened
1,701,510
$12,557,144,000 2.41%
Cincor Pharma Inc
Closed
1,019,153
$12,525,390,000
Viking Therapeutics Inc
Closed
1,295,034
$12,173,320,000
Autolus Therapeutics plc
Opened
3,441,667
$11,977,001,000 2.29%
Day One Biopharmaceuticals I
Closed
544,451
$11,716,586,000
PTC Therapeutics Inc
Closed
302,135
$11,532,493,000
Aerovate Therapeutics Inc
Closed
378,522
$11,090,695,000
Travere Therapeutics Inc
Closed
475,000
$9,989,250,000
Cymabay Therapeutics Inc
Closed
1,550,000
$9,718,500,000
Sarepta Therapeutics Inc
Closed
73,000
$9,459,340,000
Jasper Therapeutics Inc
Opened
402,015
$9,125,741,000 1.75%
Olema Pharmaceuticals, Inc.
Opened
796,880
$8,622,242,000 1.65%
Terns Pharmaceuticals Inc
Opened
1,149,406
$7,827,455,000 1.50%
Amylyx Pharmaceuticals Inc
Closed
190,000
$7,020,500,000
Moonlake Immunotherapeutics
Closed
642,566
$6,746,943,000
Erasca Inc
Closed
1,538,461
$6,630,767,000
Intercept Pharmaceuticals In
Closed
528,850
$6,541,875,000
Viridian Therapeutics Inc
Opened
500,000
$6,505,000,000 1.25%
Acumen Pharmaceuticals Inc
Closed
1,116,581
$6,029,537,000
Mirati Therapeutics Inc
Closed
133,000
$6,026,230,000
Verve Therapeutics Inc
Closed
300,000
$5,805,000,000
Albireo Pharma Inc
Closed
267,283
$5,775,986,000
Tscan Therapeutics Inc
Opened
940,831
$5,503,861,000 1.05%
Vistagen Therapeutics Inc.
Opened
1,529,338
$5,322,096,000 1.02%
Larimar Therapeutics, Inc.
Closed
1,273,635
$5,260,113,000
Helix Acquisition Corp Ii
Opened
500,000
$5,110,000,000 0.98%
Puma Biotechnology Inc
Opened
1,486,544
$4,846,133,000 0.93%
Precision BioSciences, Inc.
Closed
3,801,305
$4,523,553,000
Gracell Biotechnologies Inc.
Closed
1,962,399
$4,513,518,000
Generation Bio Co.
Closed
1,022,537
$4,018,570,000
Kyverna Therapeutics Inc
Opened
499,152
$3,743,640,000 0.72%
Spyre Therapeutics Inc
Opened
134,612
$3,164,728,000 0.61%
Alkermes plc
Closed
46,185
$1,206,814,000
Immunic, Inc.
Closed
632,184
$885,058,000
AnaptysBio Inc
66.67%
25,000
$626,500,000 0.12%
Lexicon Pharmaceuticals Inc
Opened
30,000
$50,400,000 0.01%
No transactions found
Showing first 500 out of 67 holdings